MedPath

Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease

Phase 3
Completed
Conditions
Crohn's Disease
Interventions
Drug: Placebo
Registration Number
NCT01951326
Lead Sponsor
RedHill Biopharma Limited
Brief Summary

The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.

Detailed Description

A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to Severely Active Crohn's Disease.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
331
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RHB-104RHB-1045 RHB-104 capsules administered orally BID
PlaceboPlacebo5 placebo capsules administered orally BID
Primary Outcome Measures
NameTimeMethod
Remission at Week 26Week 26

Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.

Secondary Outcome Measures
NameTimeMethod
Response at Week 26Week 26

Reduction of Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points. Lower CDAI scores indicate a better outcome.

Remission at Week 52Week 52

Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.

Durable Remission Week 26 Through Week 52Week 26 through week 52

When a subject is in remission with a maximum CDAI score of 149 at every visit from Week 26 through and including Week 52

Remission at Week 16Week 16

Reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150. Lower CDAI scores indicate a better outcome.

Steroid Free Remission at Week 52Week 52

Subjects who are maintained off steroids for a minimum of 3 weeks

Trial Locations

Locations (103)

Del Sol Research Management, 850 N Knob Road

🇺🇸

Tucson, Arizona, United States

Associated Gastroenterology Medical Group, 1211 W. La Palmak Ave, Suite 303

🇺🇸

Anaheim, California, United States

Medvin Clinical Research, 15627 Imperial Highway,

🇺🇸

La Mirada, California, United States

Digestive Care Associates, Inc., 1000 Laurel St.

🇺🇸

San Carlos, California, United States

Ventura Clinical Trials, 1835 Knoll Drive

🇺🇸

Ventura, California, United States

Medical Research Center of Connecticut, LLC

🇺🇸

Hamden, Connecticut, United States

Innovative Medical Research of South Florida, 2999 NE 191 St., Suite 330

🇺🇸

Aventura, Florida, United States

Clinical Research of West Florida

🇺🇸

Clearwater, Florida, United States

Sunrise Medical Research, Inc. 4700 N. State Road Building A, Suite 111

🇺🇸

Lauderdale Lakes, Florida, United States

Gastroenterology Group of Naples, 1064 Goodlette Road

🇺🇸

Naples, Florida, United States

Scroll for more (93 remaining)
Del Sol Research Management, 850 N Knob Road
🇺🇸Tucson, Arizona, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.